MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.29753

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2021

Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.

Razuk Victor, Camaj Anton, Cao Davide, Nicolas Johny, Hengstenberg Christian, Sartori Samantha, Zhang Zhongjie, Power David, Beerkens Frans, Chiarito Mauro, Meneveau Nicolas, Tron Christophe, Dumonteil Nicolas, Widder Julian D, Ferrari Markus, Violini Roberto, Stella Pieter R, Jeger Raban, Anthopoulos Prodromos, Mehran Roxana, Dangas George D

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

To determine the prognostic impact of anemia in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).

BACKGROUND

Whether the periprocedural use of bivalirudin as compared with UFH in anemic patients undergoing TAVR has an impact on outcomes remains unknown.

METHODS

The BRAVO-3 trial compared the use of bivalirudin versus UFH in 802 high risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence (defined as hemoglobin levels <13 g/dl in men and <12 g/dl in women) or absence of anemia. The primary outcomes were net adverse cardiac events (NACE; a composite of all-cause mortality, myocardial infarction, stroke, or bleeding) and major bleeding (Bleeding Academic Research Consortium ≥3b) at 30 days.

RESULTS

Among 798 patients with available baseline hemoglobin levels, 427 (54%) were anemic of whom 221 (52%) received bivalirudin. There were no significant differences in NACE and major bleeding at 30 days between patients with and without anemia, irrespective of the type of anticoagulant used (pinteraction  = 0.71 for NACE, pinteraction  = 1.0 for major bleeding). However, anemic patients had a higher risk of major vascular complications (adjusted OR 2.43, 95% CI 1.42-4.16, p = 0.001), and acute kidney injury (adjusted OR 1.74, 95% CI 1.16-2.59, p = 0.007) compared to non-anemic patients at 30 days.

CONCLUSIONS

Anemia was not associated with a higher risk of NACE or major bleeding at 30 days after TAVR without modification of the treatment effects of periprocedural anticoagulation with bivalirudin versus UFH.

Для цитирования: Razuk Victor, Camaj Anton, Cao Davide, Nicolas Johny, Hengstenberg Christian, Sartori Samantha, Zhang Zhongjie, Power David, Beerkens Frans, Chiarito Mauro, Meneveau Nicolas, Tron Christophe, Dumonteil Nicolas, Widder Julian D, Ferrari Markus, Violini Roberto, Stella Pieter R, Jeger Raban, Anthopoulos Prodromos, Mehran Roxana, Dangas George D. Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2021. DOI: 10.1002/ccd.29753.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.